{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:46:46Z","timestamp":1774889206645,"version":"3.50.1"},"reference-count":146,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T00:00:00Z","timestamp":1282176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec><jats:label\/><jats:p>Eur J Clin Invest 2010; 40 (10): 918\u2013931<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukaemia (CML) is a haematopoietic neoplasm characterised by the BCR\/ABL1 oncoprotein. In chronic phase CML, the neoplastic clone exhibits multilineage differentiation and maturation capacity. The BCR\/ABL1 kinase blocker imatinib shows major antileukaemic effects in most patients and is considered standard frontline therapy. However, not all patients have a long\u2010lasting response to imatinib. Notably, resistance to imatinib has been recognised as an emerging problem and challenge in CML. Whereas CML stem cells are considered to exhibit intrinsic resistance, acquired resistance may, in addition, develop in subclones over time, resulting in an overt relapse. A key trigger of resistance in subclones are <jats:italic>BCR\/ABL1<\/jats:italic> mutations. For such patients, novel multikinase inhibitors such as nilotinib, dasatinib, bosutinib or bafetinib, which block the kinase activity of various BCR\/ABL1 mutants, have been developed and reportedly exert antileukaemic effects in drug\u2010resistant cells. For highly resistant patients, haematopoietic stem cell transplantation is an alternative option. Treatment decisions and the selection of drugs are based on the presence and type of <jats:italic>BCR\/ABL1<\/jats:italic> mutation(s), phase of disease, other disease\u2010related variables and patient\u2010related factors including age, compliance and co\u2010morbidity. The current review provides an overview on standards in the diagnosis and therapy in CML, with special reference to novel BCR\/ABL1 inhibitors.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2362.2010.02328.x","type":"journal-article","created":{"date-parts":[[2010,7,6]],"date-time":"2010-07-06T20:16:55Z","timestamp":1278447415000},"page":"918-931","source":"Crossref","is-referenced-by-count":16,"title":["Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR\/ABL1 kinase inhibitor?"],"prefix":"10.1111","volume":"40","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,19]]},"reference":[{"key":"e_1_2_15_2_2","first-page":"1497","article-title":"A minute chromosome in human granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science"},{"key":"e_1_2_15_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_15_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/300765a0"},{"key":"e_1_2_15_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_15_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116786"},{"key":"e_1_2_15_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(03)70045-6"},{"key":"e_1_2_15_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.03.005"},{"key":"e_1_2_15_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21756"},{"key":"e_1_2_15_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601233140403"},{"key":"e_1_2_15_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410203311606"},{"key":"e_1_2_15_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03030-X"},{"key":"e_1_2_15_13_2","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen MH","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_15_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_15_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_15_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_15_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_15_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_15_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_15_20_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.5.24.3573"},{"key":"e_1_2_15_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404609"},{"key":"e_1_2_15_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07197.x"},{"key":"e_1_2_15_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011239"},{"key":"e_1_2_15_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004"},{"key":"e_1_2_15_25_2","article-title":"Targeting of leukemia\u2010initiating cells to develop curative drug therapies: straightforward but nontrivial concept","author":"Valent P","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"e_1_2_15_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3498"},{"key":"e_1_2_15_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"e_1_2_15_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3472"},{"key":"e_1_2_15_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07679-1"},{"key":"e_1_2_15_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-12-200612190-00008"},{"key":"e_1_2_15_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.6.2368"},{"key":"e_1_2_15_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4276"},{"key":"e_1_2_15_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403257"},{"key":"e_1_2_15_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404197"},{"key":"e_1_2_15_35_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_15_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_15_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-013250"},{"key":"e_1_2_15_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199"},{"key":"e_1_2_15_39_2","first-page":"534","article-title":"New tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"90","author":"Martinelli G","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_15_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2126"},{"key":"e_1_2_15_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2324"},{"key":"e_1_2_15_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08048.x"},{"key":"e_1_2_15_43_2","first-page":"137","article-title":"Diagnostic value of an automatic hematology analyzer in patients with hematologic disorders","volume":"15","author":"Haung ML","year":"1998","journal-title":"Adv Ther"},{"key":"e_1_2_15_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00910.x"},{"key":"e_1_2_15_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2005.00667.x"},{"key":"e_1_2_15_46_2","first-page":"2343","article-title":"The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors","volume":"94","author":"B\u00fchring HJ","year":"1999","journal-title":"Blood"},{"key":"e_1_2_15_47_2","doi-asserted-by":"publisher","DOI":"10.1309\/M9FQMQGF66167N2X"},{"key":"e_1_2_15_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.029215"},{"key":"e_1_2_15_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm343"},{"key":"e_1_2_15_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701858849"},{"key":"e_1_2_15_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404917"},{"key":"e_1_2_15_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402963"},{"key":"e_1_2_15_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2006.06.006"},{"key":"e_1_2_15_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2005.11.017"},{"key":"e_1_2_15_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870901)60:5<974::AID-CNCR2820600510>3.0.CO;2-1"},{"key":"e_1_2_15_56_2","first-page":"143","article-title":"Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome\u2010positive chronic myelogenous leukemia treated with interferon\u2010alpha: a Cancer and Leukemia Group B study","volume":"25","author":"Farag SS","year":"2004","journal-title":"Int J Oncol"},{"key":"e_1_2_15_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22936"},{"key":"e_1_2_15_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401811"},{"key":"e_1_2_15_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403157"},{"key":"e_1_2_15_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_15_61_2","first-page":"565","article-title":"Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR\u2010Abl and more","volume":"14","author":"Cea M","year":"2009","journal-title":"J Buon"},{"key":"e_1_2_15_62_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_15_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"},{"key":"e_1_2_15_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90119-X"},{"key":"e_1_2_15_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(03)70038-9"},{"key":"e_1_2_15_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.050"},{"key":"e_1_2_15_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093617"},{"key":"e_1_2_15_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"e_1_2_15_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_2_15_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_2_15_71_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_2_15_72_2","first-page":"49","article-title":"Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy","volume":"89","author":"Lange T","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_15_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.moh.0000148551.93303.9e"},{"key":"e_1_2_15_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.792"},{"key":"e_1_2_15_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404388"},{"key":"e_1_2_15_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256245"},{"key":"e_1_2_15_77_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1112"},{"key":"e_1_2_15_78_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150680"},{"key":"e_1_2_15_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.168"},{"key":"e_1_2_15_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403983"},{"key":"e_1_2_15_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.97"},{"key":"e_1_2_15_82_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_15_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_15_84_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"issue":"2","key":"e_1_2_15_85_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/shem.2003.50046","article-title":"Mutations in the ABL kinase domain pre\u2010exist the onset of imatinib treatment","volume":"40","author":"Roche\u2010Lestienne C","year":"2003","journal-title":"Semin Hematol"},{"key":"e_1_2_15_86_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-010132"},{"key":"e_1_2_15_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404318"},{"key":"e_1_2_15_88_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-066936"},{"issue":"2","key":"e_1_2_15_89_2","first-page":"260","article-title":"Comparative in vitro cellular data alone is insufficient to guide choice of BCR\u2010ABL inhibitor to treat imatinib\u2010resistant chronic myeloid leukemia","volume":"94","author":"Laneuville P","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_15_90_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10822"},{"key":"e_1_2_15_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149948"},{"key":"e_1_2_15_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.11.001"},{"key":"e_1_2_15_93_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-113969"},{"key":"e_1_2_15_94_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-038943"},{"key":"e_1_2_15_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22661"},{"key":"e_1_2_15_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22778"},{"key":"e_1_2_15_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705683"},{"key":"e_1_2_15_98_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30890"},{"key":"e_1_2_15_99_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080838"},{"key":"e_1_2_15_100_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03195613"},{"key":"e_1_2_15_101_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.6.865"},{"key":"e_1_2_15_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-008-1100-8"},{"key":"e_1_2_15_103_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_15_104_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"key":"e_1_2_15_105_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_2_15_106_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR"},{"key":"e_1_2_15_107_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02206.x"},{"key":"e_1_2_15_108_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_15_109_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_15_110_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.99.170"},{"key":"e_1_2_15_111_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001593184"},{"key":"e_1_2_15_112_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001667703"},{"key":"e_1_2_15_113_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04188"},{"key":"e_1_2_15_114_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.5608"},{"key":"e_1_2_15_115_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01859.x"},{"key":"e_1_2_15_116_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03523.x"},{"key":"e_1_2_15_117_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03881.x"},{"key":"e_1_2_15_118_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3059"},{"key":"e_1_2_15_119_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665"},{"key":"e_1_2_15_120_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402634"},{"key":"e_1_2_15_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402791"},{"key":"e_1_2_15_122_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11729"},{"key":"e_1_2_15_123_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2053"},{"key":"e_1_2_15_124_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403399"},{"key":"e_1_2_15_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2006.04.012"},{"key":"e_1_2_15_126_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11064"},{"key":"e_1_2_15_127_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-3022"},{"key":"e_1_2_15_128_2","doi-asserted-by":"publisher","DOI":"10.1159\/000023823"},{"key":"e_1_2_15_129_2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4049\/jimmunol.162.2.1032","article-title":"The mast cell as site of tissue\u2010type plasminogen activator expression and fibrinolysis","volume":"162","author":"Sillaber C","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_15_130_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613084"},{"key":"e_1_2_15_131_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084814"},{"key":"e_1_2_15_132_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4393"},{"key":"e_1_2_15_133_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104372"},{"key":"e_1_2_15_134_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702654104"},{"key":"e_1_2_15_135_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"e_1_2_15_136_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1328"},{"key":"e_1_2_15_137_2","first-page":"459","article-title":"Weekend holiday from dasatinib in CML patients not tolerating standard dosing regimens: reduced toxicity with maintained disease control","volume":"114","author":"La Rosee P","year":"2009","journal-title":"Blood"},{"key":"e_1_2_15_138_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0622"},{"key":"e_1_2_15_139_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-026377"},{"key":"e_1_2_15_140_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.112"},{"key":"e_1_2_15_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_2_15_142_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-01222-8_9"},{"key":"e_1_2_15_143_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.5075"},{"key":"e_1_2_15_144_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.021246"},{"key":"e_1_2_15_145_2","first-page":"32","volume-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","author":"Vardiman JW","year":"2008"},{"key":"e_1_2_15_146_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8853"},{"key":"e_1_2_15_147_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.193"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2010.02328.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2010.02328.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:27:17Z","timestamp":1698737237000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2010.02328.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,19]]},"references-count":146,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1365-2362.2010.02328.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02328.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,19]]}}}